PMC:7597510 / 1051-1342 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":210,"end":221},"obj":"Body_part"},{"id":"T5","span":{"begin":230,"end":241},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma82780"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma82816"}],"text":"BS) is an acute type of polyradiculoneuropathy, that occurs following immune events such as infection and vaccination. Approximately 40%–70% of GBS cases develop following infection, and autoantibodies against glycolipids (mainly ganglioside antibodies) are detected in over 50% of cases. Th"}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T20","span":{"begin":24,"end":46},"obj":"Disease"},{"id":"T21","span":{"begin":92,"end":101},"obj":"Disease"},{"id":"T22","span":{"begin":144,"end":147},"obj":"Disease"},{"id":"T23","span":{"begin":172,"end":181},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0006915"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"BS) is an acute type of polyradiculoneuropathy, that occurs following immune events such as infection and vaccination. Approximately 40%–70% of GBS cases develop following infection, and autoantibodies against glycolipids (mainly ganglioside antibodies) are detected in over 50% of cases. Th"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":210,"end":221},"obj":"Chemical"},{"id":"T2","span":{"begin":230,"end":241},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_33563"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"}],"text":"BS) is an acute type of polyradiculoneuropathy, that occurs following immune events such as infection and vaccination. Approximately 40%–70% of GBS cases develop following infection, and autoantibodies against glycolipids (mainly ganglioside antibodies) are detected in over 50% of cases. Th"}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"47","span":{"begin":230,"end":241},"obj":"Chemical"},{"id":"49","span":{"begin":24,"end":46},"obj":"Disease"},{"id":"50","span":{"begin":92,"end":101},"obj":"Disease"},{"id":"51","span":{"begin":172,"end":181},"obj":"Disease"}],"attributes":[{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D005732"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:D011129"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D007239"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"BS) is an acute type of polyradiculoneuropathy, that occurs following immune events such as infection and vaccination. Approximately 40%–70% of GBS cases develop following infection, and autoantibodies against glycolipids (mainly ganglioside antibodies) are detected in over 50% of cases. Th"}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T12","span":{"begin":119,"end":288},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"BS) is an acute type of polyradiculoneuropathy, that occurs following immune events such as infection and vaccination. Approximately 40%–70% of GBS cases develop following infection, and autoantibodies against glycolipids (mainly ganglioside antibodies) are detected in over 50% of cases. Th"}